EUVIMEDEUVIMED entdecken
Crossref

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus

Qian Chen, Jiaxuan Li, Xingxing Wang, Chen Huang, Hao Yan, Jianhua Li, Yanjun Zhang, Keda Chen iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Qian Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Repositioning, Phlebovirus, Simeprevir. Die Arbeit nennt 21 Literaturangaben. Gefördert von: This study was supported by the Medicine and health technology project of Zhejiang Province (projects number 2025KY762), the Medicine and health technology pro….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), a tick‐borne virus with high mortality, currently lacks approved antiviral therapies. In this study, we evaluated the in vitro activity of 19 FDA‐approved drugs against a clinical isolate of SFTSV using cell‐based assays, and immunofluorescence analysis. Simeprevir, Novobiocin, and Levofloxacin hydrochloride demonstrated significant antiviral activity (EC50: 0.009774, 25.12, and 46.30 μM, respectively) with minimal cytotoxicity. Immunofluorescence analysis revealed a dose‐dependent reduction in SFTSV nucleoprotein expression, correlating with decreased viral replication. The remaining 16 drugs exhibited low antiviral efficacy or high cytotoxicity. Although these three small‐molecule drugs show promise for SFTSV treatment, further in vivo studies are necessary to confirm their safety and optimize their structures. Our findings highlight the potential of drug repurposing as a strategy for developing effective therapies against emerging viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug RepositioningPhlebovirusSimeprevirHumansVirus ReplicationSevere Fever with Thrombocytopenia SyndromeAnimalsCell LineMicrobial Sensitivity TestsCell Survival

Stichwörter der Autor:innen

Simeprevirantiviral drugin vitrolevofloxacin hydrochloridenovobiocinsevere fever with thrombocytopenia syndrome virus

Substanzen

Antiviral AgentsSimeprevir

Autor:innen und Institutionen

  • School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan International Medical College, Hangzhou, Zhejiang, China.

ORCID-Profile: Keda Chen

Förderung

  • This study was supported by the Medicine and health technology project of Zhejiang Province (projects number 2025KY762), the Medicine and health technology pro…

Zitieren

APA

Chen, Q., Li, J., Wang, X., Huang, C., Yan, H., Li, J., Zhang, Y., & Chen, K. (2025). Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. Journal of Medical Virology. https://doi.org/10.1002/jmv.70655

Vancouver

Chen Q, Li J, Wang X, Huang C, Yan H, Li J, et al. Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. Journal of Medical Virology. 2025. doi:10.1002/jmv.70655

BibTeX
@article{Chen2025,
  author = {Chen, Qian and Li, Jiaxuan and Wang, Xingxing and Huang, Chen and Yan, Hao and Li, Jianhua and Zhang, Yanjun and Chen, Keda},
  title = {Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70655}
}
Kostenlos starten →